(Q28176243)

https://api.crossref.org/works/10.1592/PHCO.2005.25.6.847

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.6.847

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.6.847

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.6.847

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.6.847

Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.6.847

An Update on Aspirin in the Primary Prevention of Cardiovascular Disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.6.847

Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.6.847

Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.6.847

Final report on the aspirin component of the ongoing Physicians' Health Study

21 April 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 April 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 April 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group

21 April 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Is coronary risk an accurate surrogate for cardiovascular risk for treatment decisions in mild hypertension? A population validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Aspirin therapy in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Prospective study of aspirin use and risk of stroke in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Prophylactic aspirin and risk of peptic ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Parental history is an independent risk factor for coronary artery disease: the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Role of family history in patients with myocardial infarction. An Italian case-control study. GISSI-EFRIM Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Update on the interaction between aspirin and angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847

Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.6.847